Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate

Related Experiment Video

Updated: Aug 9, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Paola Perego1, Emilio Ciusani, Laura Gatti

  • 1Preclinical Chemotherapy and Pharmacology Unit, Department of Experimental Oncology and Laboratories, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy. paola.perego@istitutotumori.mi.it

Biochemical Pharmacology
|January 28, 2006
PubMed

Insights

Combining Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with camptothecins sensitizes prostate cancer cells to apoptosis. This combination therapy shows therapeutic potential by activating multiple cell death pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Prostate carcinoma often exhibits intrinsic resistance to apoptosis, limiting therapeutic efficacy.
  • Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and camptothecins activate distinct apoptotic pathways.

Purpose of the Study:

  • To investigate the potential of combining TRAIL with camptothecins to sensitize prostate carcinoma cells to apoptosis.
  • To elucidate the mechanisms underlying differential responses to this combination therapy in various prostate cancer cell lines.

Main Methods:

  • Treatment of androgen-independent prostate cancer cells (DU-145 and PC-3) with TRAIL and camptothecins (Topotecan, Gimatecan).
  • Assessment of apoptosis induction using Annexin V-binding assay.
  • Analysis of apoptosis-related factors including TRAIL-R1, TRAIL-R2, Akt, cFLIP-L, Bcl-2, and Bax.
  • Evaluation of the role of caspase-8 using small interfering RNA (siRNA) transfection.

Main Results:

  • Topotecan and Gimatecan moderately upregulated TRAIL-R1 and -R2 expression.
  • DU-145 cells showed increased and earlier apoptosis compared to PC-3 cells upon combination treatment.
  • PC-3 cell resistance was linked to constitutive Akt activation, higher cFLIP-L and Bcl-2, and lower Bax levels.
  • TRAIL-mediated potentiation of camptothecin-induced apoptosis involved cooperation between extrinsic and intrinsic pathways, evidenced by reduced sensitization after caspase-8 knockdown.

Conclusions:

  • The expression and activation status of apoptosis-related factors influence the sensitization of prostate carcinoma cells to TRAIL.
  • Combination therapy with TRAIL and camptothecins demonstrates therapeutic promise for prostate cancer by enhancing apoptotic responses through multiple signaling pathways.
  • The efficacy of this combination approach may depend on the intrinsic apoptotic susceptibility of individual tumors.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...